N. Takenaga

发表

Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.

R. Yoshimoto, Y. Mitobe, Sayaka Ito, 2009, Bioorganic & medicinal chemistry letters.

Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.

Sayaka Ito, Takashi Mizutani, T. Nagase, 2008, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists.

Sayaka Ito, N. Sato, S. Tokita, 2008, Bioorganic & medicinal chemistry letters.

Discovery of imidazo[1,2-a]pyridines as potent MCH1R antagonists.

H. Iwaasa, S. Sakuraba, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Discovery of novel phenylpyridone derivatives as potent and selective MCH1R antagonists.

H. Iwaasa, A. Kanatani, Masahiko Ito, 2011, Bioorganic & medicinal chemistry.

In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites.

S. Nakajima, H. Ishizaki, N. Takenaga, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Quantification of L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine (NB-355) by high-performance liquid chromatography using o-phthalaldehyde/N-acetyl-L-cysteine derivatization.

A. Hisaka, N. Takenaga, M. Ohtawa, 1989, Journal of chromatography.

Hemodynamic and Cardiac Neurotransmitter-releasing Effects in Conscious Dogs of Attention- and Wake-promoting Agents: A Comparison of d-Amphetamine, Atomoxetine, Modafinil, and a Novel Quinazolinone H3 Inverse Agonist

J. Renger, P. Tannenbaum, C. Regan, 2009, Journal of cardiovascular pharmacology.

Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers.

M. Nakashima, K. Kosuge, K. Hara, 1995, British journal of clinical pharmacology.

Metabolic Fate of Eptastigmine, a New Competitive Inhibitor of Acetylcholinesterase (I) : Absorption, Distribution and Excretion of 3H-Eptastigmine after Single Oral Administration in Rats

N. Takenaga, M. Ohtawa, Y. Kagami, 1993 .

Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.

R. Yoshimoto, T. Fukami, Y. Mitobe, 2008, Journal of medicinal chemistry.

Metabolism of rofecoxib in vitro using human liver subcellular fractions.

T. Baillie, P. Lu, B. Arison, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.

Shigeru Tokita, Shiho Ishikawa, Akane Ishihara, 2008, Journal of medicinal chemistry.

Structure-activity relationship in O-glucuronidation of indolocarbazole analogs.

N. Takenaga, T. Kamei, T. Yasumori, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Absorption of a novel prodrug of L-dopa, L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine (NB-355). In vitro and in situ studies.

A. Hisaka, N. Takenaga, M. Ohtawa, 1990, Drug metabolism and disposition: the biological fate of chemicals.

In vitro metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo+ ++[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), in mice, rats, dogs, and humans.

H. Ishizaki, N. Takenaga, T. Hasegawa, 1999, Drug metabolism and disposition: the biological fate of chemicals.

CARBAZOLE-5 , 7 ( 6 H )-DIONE ( NB-506 ) IN RATS AND DOGS : PHARMACOKINETICS , ISOLATION , IDENTIFICATION , AND QUANTIFICATION OF METABOLITES

S. Nakajima, H. Ishizaki, N. Takenaga, 1999 .

Studies on the disposion of [14C]NB-506: Plasma Concentration-Time Profile, Distribution, Metabolism and Excretion of [14C]NB-506 after Single and Repeated Intravenous Administration in Rats

H. Ishizaki, N. Takenaga, Y. Esumi, 1998 .

Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.

Kouta Masutani, M. Kameda, H. Matsushita, 2009, Bioorganic & medicinal chemistry letters.

Identification of 2-aminobenzimidazoles as potent melanin-concentrating hormone 1-receptor (MCH1R) antagonists.

H. Iwaasa, S. Sakuraba, A. Kanatani, 2009, Bioorganic & medicinal chemistry letters.

Phase I Study of Alendronate, a New Aminobisphosphonate

M. Nakashima, N. Takenaga, M. Kanamaru, 1995 .

Melanin-concentrating hormone 1-receptor antagonist suppresses body weight gain correlated with high receptor occupancy levels in diet-induced obesity mice.

D. Macneil, H. Iwaasa, H. Matsushita, 2009, European journal of pharmacology.

Absorption, Distribution, Excretion, and Sex Differences in the Disposition of the Antiosteolytic Agent, Alendronate after Oral Administration in Rats

A. Hisaka, N. Takenaga, Y. Esumi, 1998 .

Inverse agonist histamine H3 receptor PET tracers labelled with carbon‐11 or fluorine‐18

Christine Ryan, Richard Hargreaves, Shigeru Tokita, 2009, Synapse.

Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.

R. Yoshimoto, T. Fukami, Sayaka Ito, 2008, Journal of medicinal chemistry.

J. Renger, P. Tannenbaum, C. Regan, 2009, Journal of Cardiovascular Pharmacology.